ZA200907251B - Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease - Google Patents

Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease

Info

Publication number
ZA200907251B
ZA200907251B ZA2009/07251A ZA200907251A ZA200907251B ZA 200907251 B ZA200907251 B ZA 200907251B ZA 2009/07251 A ZA2009/07251 A ZA 2009/07251A ZA 200907251 A ZA200907251 A ZA 200907251A ZA 200907251 B ZA200907251 B ZA 200907251B
Authority
ZA
South Africa
Prior art keywords
oxidopyridin
cyclopropylmethoxy
carboxamide
parkinson
dichloro
Prior art date
Application number
ZA2009/07251A
Other languages
English (en)
Inventor
Christine Ravinet-Trillou
Gilles Poughon
Christine Menet
Claire% Delgorge
Philippe Delay-Goyet
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of ZA200907251B publication Critical patent/ZA200907251B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA2009/07251A 2007-04-19 2009-10-16 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease ZA200907251B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
PCT/FR2008/000534 WO2008145841A1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
ZA200907251B true ZA200907251B (en) 2011-04-28

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2009/07251A ZA200907251B (en) 2007-04-19 2009-10-16 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR101503942B1 (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500094A (ja) * 2012-11-28 2016-01-07 サノフイ 4−(シクロプロピルメトキシ)−n−(3,5−ジクロロ−1−オキシドピリジン−4−イル)−5−メトキシピリジン−2−カルボキサミドの結晶形態の製造方法およびその結晶形態
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物
US20250120957A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
JP3775685B2 (ja) * 1993-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド Pde▲iv▼およびtnf抑制剤としての化合物
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
HUP0600103A2 (en) * 2001-03-02 2006-06-28 Bristol Myers Squibb Co Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
JP2005538972A (ja) * 2002-07-02 2005-12-22 メルク フロスト カナダ アンド カンパニー ジアリール置換エタンピリドンpde4阻害剤
ES2362484T3 (es) * 2003-03-12 2011-07-06 Celgene Corporation Compuestos de ácido n-alquil-hidroxámico-isoindolilo y sus usos farmacéuticos.
AU2006257863A1 (en) * 2005-06-10 2006-12-21 F. Hoffmann-La Roche Ag Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
EA019194B1 (ru) 2014-01-30
KR20150004885A (ko) 2015-01-13
NZ580482A (en) 2011-10-28
DK2146714T3 (da) 2011-10-10
AU2008257322A1 (en) 2008-12-04
EA200970970A1 (ru) 2010-02-26
BRPI0810444A2 (pt) 2016-05-31
JP5386478B2 (ja) 2014-01-15
FR2915100B1 (fr) 2009-06-05
KR101503942B1 (ko) 2015-03-18
CA2684174C (fr) 2014-02-25
EP2146714A1 (fr) 2010-01-27
KR20090130059A (ko) 2009-12-17
WO2008145841A1 (fr) 2008-12-04
AU2008257322B2 (en) 2013-06-13
MA31367B1 (fr) 2010-05-03
RS51869B (sr) 2012-02-29
MY148092A (en) 2013-02-28
JP2010524906A (ja) 2010-07-22
PT2146714E (pt) 2011-09-02
AR066108A1 (es) 2009-07-22
PA8776801A1 (es) 2008-11-19
CL2008001136A1 (es) 2009-01-16
IL201448A0 (en) 2010-05-31
TWI439269B (zh) 2014-06-01
HRP20110666T1 (hr) 2011-10-31
FR2915100A1 (fr) 2008-10-24
CA2684174A1 (fr) 2008-12-04
JO2678B1 (en) 2013-03-03
ATE513548T1 (de) 2011-07-15
SI2146714T1 (sl) 2011-10-28
UY31035A1 (es) 2008-11-28
ME00935B (me) 2012-06-20
US20100130554A1 (en) 2010-05-27
TW200911247A (en) 2009-03-16
CN101663035A (zh) 2010-03-03
MX2009011284A (es) 2009-11-02
CY1111840T1 (el) 2015-10-07
HK1141725A1 (en) 2010-11-19
EP2146714B1 (fr) 2011-06-22
PL2146714T3 (pl) 2011-10-31
ES2367408T3 (es) 2011-11-03
IL201448A (en) 2014-08-31
CN101663035B (zh) 2012-06-20

Similar Documents

Publication Publication Date Title
IL264736B (en) Pharmaceutical preparations containing zonisamide for use in the treatment of diseases related to Alzheimer's disease
ZA200909191B (en) Catecholamine derivatives useful for the treatment of parkinson's disease
ZA201002751B (en) Compositions for treating parkinson's disease
IL192636A0 (en) Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of alzheimer's disease via gaba receptors
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
IL213259A0 (en) Composition for the use to treat alzheimer's disease
HUE043807T2 (hu) GLYX Alzheimer-kór, Parkinson-kór vagy Huntington-kór kezelésében történõ alkalmazásra
IL209896A0 (en) Compounds for treating symptoms associated with parkinson's disease
PT2229369T (pt) Derivados de 6,7-dialcoxi-quinazolina úteis para tratamento de distúrbios relacionados com o cancro
AU2008233088A8 (en) Calcimimetic compounds for use in the treatment of bowel disorders
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
IL206107A0 (en) Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
ZA200907251B (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
IL201451A0 (en) Use of 4 - cyclopropylmethoxy - n - (3, 5 - dichloro - 1 - oxidopyridin - 4 - yl) - 5 - (methoxy) pyridine - 2 - carboxamide for the treatment of spinal cord traumas
EP2214488A4 (en) COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE AND RELATED DISORDERS
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
IL201447A0 (en) Use of 4 - cyclopropylmethoxy - n - (3, 5 - dichloro - 1 - oxidopyridin - 4 - yl) - 5 - (methoxy) pyridine - 2 - carboxamide for the treatment of cranial traumas
IL194275A0 (en) Use of digitalis-like compounds in the treatment of affective disorders
GB0703787D0 (en) The treatment of fibrotic disorders
GB0700210D0 (en) The treatment of fibrotic disorders
GB0724947D0 (en) Composition for the treatment of psychiatric disorders